Patent: 5,599,673
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 5,599,673
| Title: | Long QT syndrome genes |
| Abstract: | The invention relates to the identification of the molecular basis of long QT syndrome. More specifically, the invention has identified that SCN5A and HERG cause long QT syndrome. Molecular variants of the SCN5A and HERG genes contribute to the syndrome. The analysis of these genes will provide an early diagnosis of subjects with long QT syndrome. The diagnostic methods comprise analyzing the nucleic acid sequences of the SCN5A or HERG genes of an individual to be tested and comparing them with the nucleic acid sequence of the native, nonvariant genes. Alternatively, the amino acid sequences of SCN5A or HERG may be analyzed for mutations which cause long QT syndrome. Presymptomatic diagnosis of long QT syndrome will enable practitioners to treat this disorder using existing medical therapy. |
| Inventor(s): | Keating; Mark T. (Salt Lake City, UT), Curran; Mark E. (Salt Lake City, UT), Wang; Qing (Salt Lake City, UT) |
| Assignee: | University of Utah Research Foundation (Salt Lake City, UT) |
| Application Number: | 08/401,512 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,599,673
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | See Plans and Pricing | 2039-02-26 |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | See Plans and Pricing | 2039-02-26 | |
| Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | See Plans and Pricing | 2039-02-26 | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
